Phesgo Side Effects

Generic name: hyaluronidase / pertuzumab / trastuzumab

Medically reviewed by Drugs.com. Last updated on Jan 14, 2025.

Note: This document provides detailed information about Phesgo Side Effects associated with hyaluronidase / pertuzumab / trastuzumab. Some dosage forms listed on this page may not apply specifically to the brand name Phesgo.

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution.

Precautions

It is very important that your doctor check your progress closely and at regular visits to make sure that this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.

Receiving this medicine while you are pregnant can harm your unborn baby. If you are a woman who can bear children, your doctor may give you a pregnancy test before you start receiving this medicine to make sure you are not pregnant. You should use an effective form of birth control during treatment and for at least 7 months after the last dose. If you think you have become pregnant while receiving this medicine, tell your doctor right away.

This medicine may cause heart problems, including heart failure, thickening of the heart, heart rhythm problems, or high blood pressure. Your doctor may test your heart before and during treatment with this medicine. Contact your doctor right away if you experience any chest pain, fast, slow, or uneven heartbeat, increased coughing, trouble with breathing, a sudden difficulty with breathing at night, rapid weight gain, swelling in your ankles or legs, blurred vision, dizziness, or headache.

You may also have an increased risk of having heart problems if you receive an anthracycline medicine after treatment with this medicine. You should not receive an anthracycline medicine for up to 7 months after stopping treatment with this medicine.

Serious lung or breathing problems may occur after you receive this medicine and could be life-threatening. Check with your doctor right away if have changes in your breathing, chest tightness, or any type of breathing problem.

This medicine can temporarily lower the number of some types of blood cells in your body. Because of this, you may bleed or get infections more easily. To help with these problems, avoid being near people who are sick or have infections. Wash your hands often. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.

This medicine may cause serious allergic reactions, including anaphylaxis, which can be life-threatening and requires immediate medical attention. Tell your doctor right away if you have a rash, itching, hoarseness, trouble breathing or swallowing, or any swelling of your hands, face, or mouth after receiving this medicine.

Serious side effects of Phesgo

Along with its needed effects, hyaluronidase / pertuzumab / trastuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking hyaluronidase / pertuzumab / trastuzumab:

Other side effects of Phesgo

Some side effects of hyaluronidase / pertuzumab / trastuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to hyaluronidase / pertuzumab / trastuzumab: subcutaneous solution.

Hematologic adverse events

• Very common (10% or more): Hemoglobin low (90%), absolute lymphocytes low (89%), leukocyte count low (82%), neutrophils low (68%), anemia (36%), platelets low (27%), neutropenia (22%)
• Common (1% to 10%): Leukopenia, febrile neutropenia^[Ref]

Hypersensitivity

• Common (1% to 10%): Hypersensitivity^[Ref]

Immunologic

• Common (1% to 10%): Influenza-like illness^[Ref]

Local

• Very common (10% or more): Radiation skin injury (19%), injection site reaction (15%), procedural pain (13%)
• Common (1% to 10%): Injection site pain^[Ref]

Musculoskeletal

• Very common (10% or more): Myalgia (25%), arthralgia (24%), pack pain (10%)
• Common (1% to 10%): Bone pain, pain in extremity, muscle spasms, musculoskeletal pain^[Ref]

Ocular

• Common (1% to 10%): Lacrimation increased, dry eye^[Ref]

Metabolic

• Very common (10% or more): Decreased appetite (17%), potassium low (17%), albumin low (16%), potassium high (13%), sodium low (13%), weight loss (11%)
• Common (1% to 10%): Hypokalemia, glucose low, sodium high^[Ref]

Psychiatric

• Very common (10% or more): Insomnia (17%)^[Ref]

Genitourinary

• Common (1% to 10%): Urinary tract infection^[Ref]

Hepatic

• Very common (10% or more): Alanine aminotransferase high (58%), aspartate aminotransferase high (50%)
• Common (1% to 10%): Bilirubin high

Respiratory

• Very common (10% or more): Cough (15%), epistaxis (12%), upper respiratory infection (11%), dyspnea (10%)
• Common (1% to 10%): Rhinorrhea, nasopharyngitis, paronychia
• Frequency not reported: Dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency/hypoxia, acute respiratory distress syndrome, pulmonary fibrosis, exacerbation of chemotherapy-induced neutropenia^[Ref]

Other

• Very common (10% or more): Asthenia (31%), fatigue (29%), pyrexia (13%)
• Common (1% to 10%): Edema peripheral, malaise
• Frequency not reported: Embryofetal toxicity^[Ref]

Nervous system

• Very common (10% or more): Dysgeusia (17%), headache (17%), peripheral sensory neuropathy (16%), peripheral neuropathy (12%), dizziness (13%), paresthesia (10%)^[Ref]

Renal

• Very common (10% or more): Creatinine high (84%)^[Ref]

Cardiovascular

• Very common (10% or more): Hot flush (12%), left ventricular cardiac dysfunction (LVEF)
• Common (1% to 10%): Ejection fraction decreased
• Frequency not reported: Hypertension, arrhythmias, left ventricular cardiac dysfunction, disabling cardiac failure, cardiomyopathy, cardiac death^[Ref]

Dermatologic

• Very common (10% or more): Alopecia (77%), rash (16%), dry skin (15%)
• Common (1% to 10%): Nail discoloration, erythema, dermatitis, nail disorder, palmar-plantar erythrodysesthesia syndrome
• Uncommon (0.1% to 1%): Pruritus^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (60%), diarrhea (60%), stomatitis (25%), constipation (22%), vomiting (20%), mucosal inflammation (15%), dyspepsia (14%)
• Common (1% to 10%): Hemorrhoids, abdominal pain, abdominal pain upper^[Ref]

See also:

Further information

Phesgo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer